779 related articles for article (PubMed ID: 28578456)
1. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
[TBL] [Abstract][Full Text] [Related]
3. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
[TBL] [Abstract][Full Text] [Related]
4. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF
Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089
[TBL] [Abstract][Full Text] [Related]
5. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
[TBL] [Abstract][Full Text] [Related]
6. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
7. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
Su JC; Mar AC; Wu SH; Tai WT; Chu PY; Wu CY; Tseng LM; Lee TC; Chen KF; Liu CY; Chiu HC; Shiau CW
Sci Rep; 2016 Jul; 6():28888. PubMed ID: 27364975
[TBL] [Abstract][Full Text] [Related]
8. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
[TBL] [Abstract][Full Text] [Related]
9. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.
Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
Neoplasia; 2015 Sep; 17(9):687-696. PubMed ID: 26476076
[TBL] [Abstract][Full Text] [Related]
12. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
[TBL] [Abstract][Full Text] [Related]
13. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
Su TH; Shiau CW; Jao P; Yang NJ; Tai WT; Liu CJ; Tseng TC; Yang HC; Liu CH; Huang KW; Hu TC; Huang YJ; Wu YM; Chen LJ; Chen PJ; Chen DS; Chen KF; Kao JH
Sci Rep; 2017 May; 7(1):1728. PubMed ID: 28496142
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
15. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
16. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW
Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
[TBL] [Abstract][Full Text] [Related]
18. SHP-1 is a target of regorafenib in colorectal cancer.
Fan LC; Teng HW; Shiau CW; Lin H; Hung MH; Chen YL; Huang JW; Tai WT; Yu HC; Chen KF
Oncotarget; 2014 Aug; 5(15):6243-51. PubMed ID: 25071018
[TBL] [Abstract][Full Text] [Related]
19. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]